The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Schizophrenia Research

• Publication date

  2006-05-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/J.SCHRES.2006.03.023PMID 16632329
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vitamin E for neuroleptic-induced tardive dyskinesia.

  2011cited by this paper
• Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.

  2006cited by this paper
• Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia.

  2006cited by this paper
• Benzodiazepines for neuroleptic‐induced tardive dyskinesia

  2006cited by this paper
• Ethyl-EPA in Huntington disease

  2005cited by this paper
• Acupuncture for schizophrenia.

  2005cited by this paper
• Tardive Dyskinesia in the Era of Typical and Atypical Antipsychotics. Part 2: Incidence and Management Strategies in Patients with Schizophrenia

  2005cited by this paper
• Manual for the Extrapyramidal Symptom Rating Scale (ESRS).

  2005cited by this paper
• Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

  2005cited by this paper
• A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia.

  2004cited by this paper
• Contents of The American Journal of Psychiatry

  2004cited by this paper
• Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.

  2004cited by this paper
• Benzodiazepines for neuroleptic-induced tardive dyskinesia.

  2003cited by this paper
• Miscellaneous treatments for neuroleptic-induced tardive dyskinesia.

  2003cited by this paper
• Melatonin for the Treatment of Tardive Dyskinesia

  2003cited by this paper
• Clinical Potential of Omega-3 Fatty Acids in the Treatment of Schizophrenia

  2003cited by this paper
• Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men.

  2003cited by this paper
• Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia.

  2002influential reference
• Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.

  2001cited by this paper
• Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.

  2001cited by this paper
• Miscellaneous treatments for neuroleptic-induced tardive dyskinesia.

  2000cited by this paper
• Calcium channel blockers for neuroleptic-induced tardive dyskinesia.

  2000cited by this paper
• Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.

  2000cited by this paper
• Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol.

  1999cited by this paper
• Treatment of schizophrenia in low-income countries.

  1999cited by this paper
• The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia.

  1998cited by this paper
• Cholinergic medication for neuroleptic-induced tardive dyskinesia.

  1997cited by this paper
• Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.

  1997cited by this paper
• Schizophrenia, tardive dyskinesia and essential fatty acids.

  1996cited by this paper
• Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation.

  1996cited by this paper
• Clozapine in tardive dyskinesia: observations from human and animal model studies.

  1994cited by this paper
• Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design.

  1993cited by this paper
• Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association

  1993cited by this paper
• The Effects of Clozapine on Tardive Dyskinesia

  1991cited by this paper
• A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia.

  1989cited by this paper
• Tardive dyskinesia: prevalence, incidence, and risk factors.

  1988cited by this paper
• Pharmacologic studies of tardive dyskinesia.

  1988cited by this paper
• Treatment of tardive dyskinesia.

  1988cited by this paper
• The positive and negative syndrome scale (PANSS) for schizophrenia.

  1987cited by this paper
• Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures.

  1984cited by this paper
• Tardive dyskinesia--reversible and persistent.

  1979cited by this paper
• Nutritional properties of fish oils.

  1969cited by this paper

• Efficacy and safety of anti-inflammatory drug-assisted treatment of symptoms in patients with schizophrenia: a meta-analysis

  2026cites this paper
• The therapeutic effect of omega-3 polyunsaturated fatty acids on symptom severity of psychosis: A systematic review and meta-analysis

  2024cites this paper
• Impacts of Omega-3 Fatty Acids, Natural Elixirs for Neuronal Health, on Brain Development and Functions.

  2024cites this paper
• RETRACTED ARTICLE: Efficacy and safety of different pharmacological interventions in the treatment of tardive dyskinesia: a systematic review and network meta-analysis

  2024cites this paper
• Efficacy and acceptability of pharmacological interventions for tardive dyskinesia in people with schizophrenia or mood disorders: a systematic review and network meta-analysis

  2024cites this paper
• Nutrition in the Treatment of Schizophrenia: Rationale and Review of Recent Evidence

  2023cites this paper
• Nutrition and schizophrenia: associations worthy of continued revaluation

  2023cites this paper
• Recent Reports on Redox Stress-Induced Mitochondrial DNA Variations, Neuroglial Interactions, and NMDA Receptor System in Pathophysiology of Schizophrenia

  2022cites this paper
• Anti-inflammatory Agents for Patients with Schizophrenia

  2021cites this paper
• Longitudinal investigation of the relationship between omega-3 polyunsaturated fatty acids and neuropsychological functioning in recent-onset psychosis: A randomized clinical trial.

  2021cites this paper
• Increased PLA2 activity in individuals at ultra-high risk for psychosis

  2021cites this paper
• Effects of omega-3 polyunsaturated fatty acids supplements on psychopathology and metabolic parameters in schizophrenia: A meta-analysis of randomized controlled trials

  2021cites this paper
• Oxidative Stress-Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives

  2021cites this paper
• Schizophrenia and Related Psychoses

  2021cites this paper
• Are omega-3 fatty acids efficacious in the treatment of depression? A review

  2021cites this paper
• A Systematic Review of Effectiveness of Omega-3 Fatty Acid Supplementation on Symptoms, Social Functions, and Neurobiological Variables in Schizophrenia

  2021cites this paper
• Effects of Omega 3 Fatty Acids on Main Dimensions of Psychopathology

  2020cites this paper
• Omega-3 fatty acids in cause, prevention and management of violence in schizophrenia: Conceptualization and application

  2020cites this paper
• Lipids in the Treatment of Mental Disorders

  2020cites this paper
• Omega-3 Polyunsaturated Fatty Acids and Antioxidants for the Treatment of Schizophrenia: A Role for Magnetic Resonance Imaging

  2020cites this paper
• No Impact of Omega-3 Fatty Acid Supplementation on Symptoms or Hostility Among Patients With Schizophrenia

  2020cites this paper
• Patient Stratification Using Metabolomics to Address the Heterogeneity of Psychosis

  2020cites this paper
• Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders - a comprehensive systematic review and meta-analysis.

  2020cites this paper
• Omega-3 fatty acids and mental health

  2020cites this paper
• Beneficial effects of omega-3 fatty acid supplementation in schizophrenia: possible mechanisms

  2020cites this paper
• Neurobiological Meaning of Omega-3 Fatty Acids and Their Potential Role in the Treatment of Schizophrenia

  2019cites this paper
• An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis

  2019cites this paper
• Adjunctive use of anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials

  2019cites this paper
• Are there serious adverse effects of omega-3 polyunsaturated fatty acid supplements?

  2019cites this paper
• A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone.

  2019cites this paper
• The effects of bioavailable omega-3 polyunsaturated fatty acids, delivered at bedtime, on brain function, sleep, cognition and mood in healthy adults

  2019cites this paper
• Polyunsaturated Fatty Acids: What is Their Role in Treatment of Psychiatric Disorders?

  2019cites this paper
• Natural Medicines for Psychotic Disorders

  2018cites this paper
• Assessment of the efficacy of omega-3 fatty acids on metabolic and inflammatory parameters in patients with schizophrenia taking clozapine and sodium valproate.

  2018cites this paper
• Miscellaneous treatments for antipsychotic-induced tardive dyskinesia.

  2018cites this paper
• Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm.

  2018cites this paper
• Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia.

  2017cites this paper
• Effects of Omega-3 in the treatment of violent schizophrenia patients.

  2017cites this paper
• Movement and nutrition in health and disease

  2017cites this paper
• Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management

  2017cites this paper
• Nutritional supplements in psychotic disorders.

  2017cites this paper
• EFFECTS OF OPTOGENETIC ACTIVATION AND PHARMACOLOGICAL MODULATION OF DOPAMINE NEURONS

  2016cites this paper
• Supplementation with Omega-3 Fatty Acids in Psychiatric Disorders: A Review of Literature Data

  2016cites this paper
• A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia.

  2016influential citation
• A Meta-Analysis of Placebo-Controlled Trials of Omega-3 Fatty Acid Augmentation in Schizophrenia: Possible Stage-Specific Effects

  2015cites this paper
• Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials

  2015cites this paper
• Inflammation in schizophrenia: A question of balance.

  2015cites this paper
• Tardive dyskinesia (syndrome): Current concept and modern approaches to its management

  2015cites this paper
• Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA

  2015cites this paper
• Omega 3 Fatty Acids: Novel Neurotherapeutic Targets for Cognitive Dysfunction in Mood Disorders and Schizophrenia?

  2015cites this paper
• Immunology and Psychiatry

  2015cites this paper
• Polyunsaturated Fatty Acids in Adult Psychiatric Disorders: A Comprehensive Overview

  2015cites this paper
• Drug repurposing and emerging adjunctive treatments for schizophrenia

  2015cites this paper
• Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods

  2015cites this paper
• Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update.

  2014cites this paper
• Polyunsaturated fatty acids in emerging psychosis: a safer alternative?

  2014cites this paper
• [Immunological treatment options for schizophrenia].

  2014influential citation
• Der Einfluss von Clozapin, N-Desmethylclozapin und Chlorpromazin auf die in-vitro-Produktion von Thromboxan

  2014cites this paper
• Omega-3 Fatty Acids in Intellectual Disability, Schizophrenia, Depression, Autism, and Attention-Deficit Hyperactivity Disorder

  2014cites this paper
• Natural Medicines in Schizophrenia: A Systematic Review

  2014cites this paper
• A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia.

  2014cites this paper
• Randomized, Placebo-Controlled Clinical Trial of Omega-3 as Supplemental Treatment in Schizophrenia

  2014cites this paper
• N-3 fatty acids for hypertriglyceridemia in patients taking second-generation antipsychotics.

  2013cites this paper
• Treatment of neurolept-induced tardive dyskinesia

  2013cites this paper
• The role of anti-inflammatory treatment in psychiatric disorders.

  2013cites this paper
• Omega-3 fatty acids and schizophrenia: evidences and recommendations.

  2013cites this paper
• Anti-inflammatory treatment in schizophrenia.

  2013cites this paper
• Mechanisms of Involvement of Eicosanoids and their Precursors in the Pathophysiology and Treatment of Schizophrenia.

  2013cites this paper
• Treatment of tardive dyskinesia: a systematic review (1997-2011)

  2013cites this paper
• [Tardive dyskinesia: diagnosis, assessment and treatment].

  2013cites this paper
• Long-Chain Omega-3 Fatty Acids and Psychotic Disorders

  2013cites this paper
• Eficacia de los ácidos grasos omega-3 como tratamiento suplementario en la esquizofrenia

  2013cites this paper
• Onverzadigde vetzuren en schizofrenie

  2013cites this paper
• An Evidence-based Approach to Phytochemicals and Other Dietary Factors

  2012cites this paper
• Drug-Induced Hyperkinetic Movement Disorders

  2012cites this paper
• Cortical interneurons, immune factors and oxidative stress as early targets for schizophrenia

  2012cites this paper
• Immunological treatment options for schizophrenia.

  2012cites this paper
• Inflammation in schizophrenia.

  2012cites this paper
• Eicosapentaenoic Acid Interventions in Schizophrenia: Meta-Analysis of Randomized, Placebo-Controlled Studies

  2012cites this paper
• A review of the possible role of the essential fatty acids and fish oils in the aetiology, prevention or pharmacotherapy of schizophrenia

  2012influential citation
• Polyunsaturated fatty acids in emerging psychosis.

  2012cites this paper
• Esquizofrenia: abordagens terapêuticas não-farmacológicas.

  2012cites this paper
• Effects of vitamins, fatty acids, minerals, and other dietary supplements on schizophrenic symptoms in people with schizophrenia

  2011influential citation
• Drug therapies for tardive dyskinesia: part 2.

  2011cites this paper
• Evaluation of negative and positive health effects of n-3 fatty acids as constituents of food supplements and fortified Foods. Opinion of the Steering Committee of the Norwegian Scientific Committee for Food Safety

  2011cites this paper
• Oxidative Stress in Schizophrenia

  2011cites this paper
• Advancing Neuroprotective-Based Treatments for Schizophrenia

  2011cites this paper
• Motor Symptoms of Schizophrenia: Is Tardive Dyskinesia a Symptom or Side Effect? A Modern Treatment

  2011cites this paper
• Antioxidants as a Treatment and Prevention of Tardive Dyskinesia

  2011cites this paper
• The Use of Omega-3 Fatty Acids in Mental Illness

  2011cites this paper
• Subjective awareness of tardive dyskinesia and insight in schizophrenia

  2011cites this paper
• Hostility of drug-free patients with schizophrenia and n-3 polyunsaturated fatty acid levels in red blood cells.

  2010cites this paper
• Rola wielonienasyconych kwasów tłuszczowych omega-3 w etiopatogenezie i leczeniu zaburzeń psychicznych

  2010cites this paper
• Effects of ω-3 Essential Fatty Acids (ω-3 EFAs) on Motor Disorders and Memory Dysfunction Typical Neuroleptic-induced: Behavioral and Biochemical Parameter

  2010cites this paper
• Changes in erythrocyte membrane fatty acids during a clinical trial of eicosapentaenoic acid (EPA) supplementation in schizophrenia

  2009influential citation
• Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines.

  2009cites this paper
• Essential fatty acids and human brain.

  2009cites this paper
• Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis. A 1H-MRS Study

  2008cites this paper
• Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study.

  2008cites this paper
• Omega-3 polyunsaturated fatty acids in the treatment of schizophrenia.

  2008cites this paper